International Journal of Internal Medicine

Objective To observe the effect of mosapride and rabeprazole in the treatment of chronic gastritis. Methods According to the way of comparative treatment and observation of included cases, 60 patients were selected in total, and the time was from February 2021 to May 2022. The blind selection was divided into the control group (30 cases, conventional treatment) and the observation group (30 cases, treated with mosapride and rabeprazole). Analyze the treatment effect. Results Compared with the control group, the improvement time of nausea and vomiting symptoms, belching relief time and pain relief time in the observation group were shorter than those in the control group (P<0.05). Compared the levels of serum C-reactive protein, interleukin-6 and interleukin-10 between the two groups, there was no difference between the two groups before treatment (P>0.05), and the observation group was superior to the control group after treatment (P<0.05). Conclusion Mosapride and rabeprazole can promote the rapid improvement of corresponding symptoms, reduce the level of inflammatory reaction in patients with chronic gastritis, and help patients recover.

Mosapride; Rabeprazole; chronic gastritis